Chewtadzy 5 mg — CareFirst (Caremark)

Initial criteria

• Authorization may be granted when the requested drug is being prescribed for daily use for symptomatic benign prostatic hyperplasia (BPH).

Reauthorization criteria

• Authorization may be granted when the requested drug is being prescribed for daily use for symptomatic benign prostatic hyperplasia (BPH) when the following criterion is met:
• • The patient has achieved or maintained a positive clinical response to the requested drug.

Approval duration

36 months